Charalampos-Vlasios Stikas

Charalampos-Vlasios Stikas

Auto-generated profile, based on publicly available information

Charalampos-Vlasios Stikas

Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2023 in JHEP Reports
Verified
Journal Article
Open access
CFClaudia Angela Maria Fulgenzi
Claudia Angela Maria Fulgenzi
BSbernhard scheiner
bernhard scheiner
JKJames Korolewicz
James Korolewicz
CSCharalampos-Vlasios Stikas
Charalampos-Vlasios Stikas
AGAlessandra Gennari
Alessandra Gennari
David James PinatoDavid James Pinato
David James Pinato
Direct comparisons across first-line regimens for advanced hepatocellular carcinoma are not available. We performed a network metanalysis of phase III of trials to compare first-line systemic treatments for hepatocellular carcinoma in terms of overall survival (OS), progression-free survival (PFS), objective response rate, disease control rate, and incidence of adverse events (AEs). After performing a literature review from January 2008 to September 2022, we screened 6,329 studies and reviewed 3,009 studies, leading to identification of 15 phase III trials for analysis. We extracted odds ratios for objective response rate and disease control rate, relative risks for AEs, and hazard ratios (HRs) with 95% CIs for OS and PFS, and used a frequentist network metanalysis, with fixed-effect multivariable meta-regression models to estimate the indirect pooled HRs, odds ratios, relative risks, and corresponding 95% CIs, considering sorafenib as reference. Of 10,820 included patients, 10,444 received active treatment and 376 placebo. Sintilimab + IBI350, camrelizumab + rivoceranib, and atezolizumab + bevacizumab provided the greatest reduction in the risk of death compared with sorafenib, with HRs of 0.57 (95% CI 0.43-0.75), 0.62 (95% CI 0.49-0.79), and 0.66 (95% CI 0.52-0.84), respectively. Considering PFS, camrelizumab + rivoceranib and pembrolizumab + lenvatinib were associated with the greatest reduction in the risk of PFS events compared with sorafenib, with HRs of 0.52 (95% CI 0.41-0.65) and 0.52 (95% CI 0.35-0.77), respectively. Immune checkpoint inhibitor (ICI) monotherapies carried the lowest risk for all-grade and grade ≥3 AEs. The combinations of ICI + anti-vascular endothelial growth factor, and double ICIs lead to the greatest OS benefit compared with sorafenib, whereas ICI + kinase inhibitor regimens are associated with greater PFS benefit at the cost of higher toxicity rates. In the last few years, many different therapies have been studied for patients with primary liver cancer that cannot be treated with surgery. In these cases, anticancer drugs (alone or in combination) are given with the intent to keep the cancer at bay and, ultimately, to prolong survival. Among all the therapies that have been investigated, the combination of immunotherapy (drugs that boost the immune system against the cancer) and anti-angiogenic agents (drugs that act on tumoural vessels) has appeared the best to improve survival. Similarly, the combination of two types of immunotherapies that activate the immune system at different levels has also shown positive results. PROSPERO CRD42022366330.

5 April 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
David James PinatoDavid James Pinato
David James Pinato
ADAntonio D'Alessio
Antonio D'Alessio
CFClaudia Fulgenzi
Claudia Fulgenzi
ASAlexandra Emilia Schlaak
Alexandra Emilia Schlaak
CCCiro Celsa
Ciro Celsa
RSRohini Sharma
Rohini Sharma
Purpose: Transarterial chemoembolization (TACE) may prime adaptive immunity and enhance immunotherapy efficacy. PETAL evaluated safety, preliminary activity of TACE plus pembrolizumab and explored mechanisms of efficacy. Patients and Methods: Patients with liver-confined hepatocellular carcinoma (HCC) were planned to receive up to two rounds of TACE followed by pembrolizumab 200 mg every 21 days commencing 30 days post-TACE until disease progression or unacceptable toxicity for up to 1 year. Primary endpoint was safety, with assessment window of 21 days from pembrolizumab initiation. Secondary endpoints included progression-free survival (PFS) and evaluation of tumor and host determinants of response. Results: Fifteen patients were included in the safety and efficacy population: 73% had nonviral cirrhosis; median age was 72 years. Child-Pugh class was A in 14 patients. Median tumor size was 4 cm. Ten patients (67%) received pembrolizumab after one TACE; 5 patients after two (33%). Pembrolizumab yielded no synergistic toxicity nor dose-limiting toxicities post-TACE. Treatment-related adverse events occurred in 93% of patients, most commonly skin rash (40%), fatigue, and diarrhea (27%). After a median follow-up of 38.5 months, objective response rate 12 weeks post-TACE was 53%. PFS rate at 12 weeks was 93% and median PFS was 8.95 months [95% confidence interval (CI): 7.30–NE (not estimable)]. Median duration of response was 7.3 months (95% CI: 6.3–8.3). Median overall survival was 33.5 months (95% CI: 11.6–NE). Dynamic changes in peripheral T-cell subsets, circulating tumor DNA, serum metabolites, and in stool bacterial profiles highlight potential mechanisms of action of multimodal therapy. Conclusions: TACE plus pembrolizumab was tolerable with no evidence of synergistic toxicity, encouraging further clinical development of immunotherapy alongside TACE.

8 March 2023 in Clinical & Experimental Allergy
Verified
Journal Article
Open access
MIManal Bel Imam
Manal Bel Imam
CSCharalampos‐Vlasios Stikas
Charalampos‐Vlasios Stikas
PGPayal Guha
Payal Guha
BCBo L. Chawes
Bo L. Chawes
DCDerek Chu
Derek Chu
CCCore Outcome Measures for Food Allergy (COMFA) consortium
Core Outcome Measures for Food Allergy (COMFA) consortium
BackgroundMixed and non-IgE-mediated food allergy is a subset of immune-mediated adverse food reactions that can impose a major burden on the quality of life of affected patients and their families. Clinical trials to study these diseases are reliant upon consistent and valid outcome measures that are relevant to both patients and clinicians, but the degree to which such stringent outcome reporting takes place is poorly studied. ObjectiveAs part of the Core Outcome Measures for Food Allergy (COMFA) project, we identified outcomes reported in randomized clinical trials (RCT) of treatments for mixed or non-IgE-mediated food allergy. DesignIn this systematic review, we searched the Ovid, MEDLINE and Embase databases for RCTs in children or adults investigating treatments for food protein-induced enterocolitis syndrome, food protein-induced allergic proctocolitis, food protein-induced enteropathy and eosinophilic gastrointestinal disorders including eosinophilic esophagitis [EoE], eosinophilic gastritis and eosinophilic colitis published until 14 October 2022. ResultsTwenty-six eligible studies were identified, with 23 focused on EoE (88%). Most interventions were corticosteroids or monoclonal antibodies. All EoE studies assessed patient-reported dysphagia, usually using a non-validated questionnaire. Twenty-two of 23 EoE studies used peak tissue eosinophil count as the primary outcome, usually using a non-validated assessment method, and other immunological markers were only exploratory. Thirteen (57%) EoE studies reported endoscopic outcomes of which six used a validated scoring tool recently recommended as a core outcome for EoE trials. Funding source was not obviously associated with likelihood of an RCT reporting mechanistic versus patient-reported outcomes. Only 3 (12%) RCTs concerned forms of food allergy other than EoE, and they reported on fecal immunological markers and patient-reported outcomes. ConclusionsOutcomes measured in clinical trials of EoE and non-IgE-mediated food allergy are heterogeneous and largely non-validated. Core outcomes for EoE have been developed and need to be used in future trials. For other forms of mixed or non-IgE-mediated food allergies, core outcome development is needed to support the development of effective treatments. Systematic review registrationOSF public registry DOI:10.17605/OSF.IO/AZX8S

3 June 2024
Verified
Other
Open access
David James PinatoDavid James Pinato
David James Pinato
ADAntonio D'Alessio
Antonio D'Alessio
CFClaudia Fulgenzi
Claudia Fulgenzi
ASAlexandra Emilia Schlaak
Alexandra Emilia Schlaak
CCCiro Celsa
Ciro Celsa
RSRohini Sharma
Rohini Sharma
Supplementary Figure S14. Alpha and beta diversity measures of stool samples collected at screening were compared with samples collected at the end of treatment (EOT). Violin plots represent the lack of significant differences in Shannon’s diversity and Chao1’s richness (A-B), while the principal coordinate analysis charts are used to plot Bray-Curtis’s diversity and Jaccard’s richness (C-D) The volcano plot in Panel E represents the different gut microbiota composition at a genus level across timepoints. Abbreviation: NS, non significant; EOT, end of treatment.


3 June 2024
Verified
Other
Open access
David James PinatoDavid James Pinato
David James Pinato
ADAntonio D'Alessio
Antonio D'Alessio
CFClaudia Fulgenzi
Claudia Fulgenzi
ASAlexandra Emilia Schlaak
Alexandra Emilia Schlaak
CCCiro Celsa
Ciro Celsa
RSRohini Sharma
Rohini Sharma
Supplementary Figure S2. Custom-developed bioinformatic variant calling pipeline to identify somatic SNVs and indels